SCHEMBL2197185

SCHEMBL2197185

COc1ccc(Cn2ccn(C)c2=[Pt])cc1OC.IN(I)C12CCC(CC1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.42
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 3/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA2C P18825 1/20 0.35
CHRM3 P20309 1/20 0.35
HRH2 P25021 1/20 0.35
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35
HTR7 P34969 1/20 0.35
ADRA1B P35368 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRK1 P41145 1/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
CA2 P00918 3/20 0.33
CA1 P00915 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195127 0.86 MAPT (0.36) SIGMAR1ALDH1A1KDM4EGAAMAPT
SCHEMBL2195084 0.84 SIGMAR1 (0.46) SIGMAR1MAPK1ALDH1A1KMT2AMEN1
SCHEMBL2192101 0.83 SIGMAR1 (0.45) SIGMAR1MAPK1ALDH1A1KMT2AMEN1
SCHEMBL2192874 0.82 SIGMAR1 (0.44) SIGMAR1MAPK1ALDH1A1KMT2AMEN1
SCHEMBL2194519 0.81 SIGMAR1 (0.43) SIGMAR1MAPK1ALDH1A1KMT2AMEN1
SCHEMBL2192469 0.81 SIGMAR1 (0.43) SIGMAR1MAPK1ALDH1A1KMT2AMEN1
SCHEMBL2192457 0.78 MAPT (0.42) SIGMAR1MAPK1ALDH1A1KMT2AMEN1
SCHEMBL2194560 0.77 L3MBTL1 (0.41) SIGMAR1MAPK1LMNA
SCHEMBL2195285 0.76 LMNA (0.39) SIGMAR1ALDH1A1KMT2AMEN1GAA
SCHEMBL2194395 0.76 MAPK10 (0.38) SIGMAR1MAPK1KMT2AMEN1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 SIGMAR1 259/4885MAPK1 3174/4885ALDH1A1 1989/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 SIGMAR1 259/4885MAPK1 3174/4885ALDH1A1 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.